文献速递心脑血管急症消化、代谢与肾脏急症

利用医疗保健数据库支持已批准药物的补充适应症

Use of Health Care Databases to Support Supplemental Indications of Approved Medications.
PubMed 文献 · JAMA Intern Med · 2018-01-01
一句话结论在常规诊疗人群中,替米沙坦与雷米普利的心梗、卒中或心衰住院复合风险相似(HR 1.0),替米沙坦血管性水肿风险更低(HR 0.1),与ONTARGET试验结果一致。

本研究利用2003年1月1日至2009年9月30日全国性医疗保险索赔数据库,纳入新处方替米沙坦或雷米普利的患者,复现ONTARGET试验的纳入和排除标准,并用倾向性评分匹配平衡74项患者特征。共纳入640951例患者,匹配后替米沙坦组和雷米普利组各4665例。主要终点为心肌梗死、卒中或充血性心力衰竭住院的复合终点,两组风险相似(HR 1.0;95%CI 0.9-1.1),与ONTARGET结果一致;替米沙坦组血管性水肿风险显著低于雷米普利组(HR 0.1;95%CI 0.03-0.56)。作者认为,在特定情况下,数据库研究可能为已批准药物的有效性补充申请提供支持。

要点

  • 匹配后替米沙坦组与雷米普利组主要复合终点(心梗、卒中或心衰住院)风险相似:HR 1.0(95%CI 0.9-1.1)。
  • 替米沙坦组血管性水肿风险低于雷米普利组:HR 0.1(95%CI 0.03-0.56)。
  • 该数据库分析复现了ONTARGET试验的纳入和排除标准,并用倾向性评分匹配平衡74项患者特征。
  • 作者认为,在特定情况下,数据库研究可能支持已批准药物的有效性补充申请。

适用人群与场景

  • 新处方替米沙坦或雷米普利的患者,来自2003年1月1日至2009年9月30日全国性医疗保险索赔数据库。
  • 研究复现了ONTARGET试验的纳入和排除标准。

研究设计与关键结果

  • 研究类型为队列研究,使用全国性医疗保险索赔数据库,纳入640951例患者,其中新处方雷米普利48053例(平均[SD]年龄68.29[9.52]岁;男性31940例[66.5%]),新处方替米沙坦4665例(平均[SD]年龄69.43[9.60]岁;男性2413例[51.7%])。
  • 倾向性评分匹配后,替米沙坦组4665例(平均[SD]年龄69.43[9.60]岁;男性2413例[51.7%]),雷米普利组4665例(平均[SD]年龄69.36[9.67]岁;男性2343例[50.2%])。
  • 主要复合终点(心肌梗死、卒中或充血性心力衰竭住院)风险两组相似:HR 1.0(95%CI 0.9-1.1),与ONTARGET试验结果一致。
  • 替米沙坦组血管性水肿风险低于雷米普利组:HR 0.1(95%CI 0.03-0.56)。

证据类型、等级与局限

  • 证据类型:队列研究(使用医疗保险索赔数据库)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在特定情况下,数据库研究可能支持已批准药物的有效性补充申请。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Manufacturers of US Food and Drug Administration-approved prescription drugs often apply for additional indications based on randomized clinical trials. Real-world database analyses on a medication's use and outcomes in routine settings of care might help to inform decision making regarding such supplemental indications.

OBJECTIVE: To examine whether longitudinal data from a health care database can support the results of a randomized clinical trial that led to a supplemental indication for telmisartan.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study of patients newly prescribed telmisartan or ramipril used insurance claims data from a nationwide health care database from January 1, 2003, through September 30, 2009, to compare patient outcomes. This study replicated the inclusion and exclusion criteria used in the Ongoing Telmisartan Alone and in Combination with Ramipril Global End-point Trial (ONTARGET) and used propensity score matching to balance 74 patient characteristics. Data analysis was performed from February 15, 2017, to May 24, 2017.

EXPOSURES: Telmisartan use vs ramipril use.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of myocardial infarction, stroke, or hospitalization for congestive heart failure.

RESULTS: Of the 640 951 patients included in the study, 48 053 were newly prescribed ramipril (mean [SD] age, 68.29 [9.52] years; 31 940 male [66.5%]) and 4665 were newly prescribed telmisartan (mean [SD] age, 69.43 [9.60] years; 2413 male [51.7%]). After propensity score matching, a total of 4665 patients were newly prescribed telmisartan (mean [SD] age, 69.43 [9.60] years; 2413 [51.7%]), and 4665 patients were newly prescribed ramipril (mean [SD] age, 69.36 [9.67] years; 2343 male [50.2%]). As seen in ONTARGET, the composite risk of stroke, myocardial infarction, and hospitalization for congestive heart failure was similar for the 2 medications (hazard ratio, 1.0; 95% CI, 0.9-1.1). In addition, the study found that telmisartan was associated with a substantially decreased risk of angioedema (hazard ratio, 0.1; 95% CI, 0.03-0.56) compared with ramipril.

CONCLUSIONS AND RELEVANCE: Real-world data analyses of patients receiving routine care provided findings similar to those found in the randomized clinical trial that established telmisartan's supplemental indication. In certain situations, database studies may support supplemental applications for effectiveness for already approved medications.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Fralick M, Kesselheim AS, Avorn J, et al. Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018. PMID: 29159410. doi:10.1001/jamainternmed.2017.3919

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。